Comparison of contraceptive pills reveals differences in adverse metabolic effects between different estrogen compounds

18 June 2020

Estradiol, the major estrogen sex hormone in humans and a widely used medication. Credit: Public Domain

A joint study by the University of Oulu and University of Helsinki, Finland, compared the effects of two different types of estrogen in combined contraceptives (COCs) on blood inflammatory markers and lipid levels. Similar comparisons between these two types of estrogens have never been done before.

Fifty-nine healthy women aged between 18 and 34 years participated in the study, using a COC containing either ethinyl estradiol or estradiol valerate, or a product containing only progestin, continuously for nine weeks.

The COC containing ethinyl estradiol increased chronic inflammation. The result was not surprising, as ethinyl estradiol has previously been observed to slightly increase inflammatory markers.

The comparison with estradiol is, however, a novel finding. Estradiol valerate did not increase inflammatory markers and had metabolic effects similar to contraceptive only including progestin.

An overwhelming majority of the currently available COCs contain ethinyl estradiol. "There are dozens of COCs with ethinyl estradiol combinations available in the market, whereas there are only three COCs used in Finland that contain natural estradiol or estradiol valerate," says Marika Kangasniemi from the University of Oulu, head researcher of the study.

Increased chronic low-grade inflammation is known to predispose women to cardiovascular diseases. Although the study gives a strong indication to favour estradiol valerate in COCs, further research is still needed with long term effects of COCs and to see if recommendation favouring estradiol over ethinyl estradiol in COCs can be given.

"Because women use COCs for up to decades, it could be useful to favour COCs with fewer adverse metabolic effects. In particular, this should be taken into account for women who already have many metabolic risk factors, such as obesity or polycystic ovary syndrome. However, more medical research with these patient groups is needed," says Kangasniemi.

The study was published in the Journal of Clinical Endocrinology & Metabolism.
